Medidata & Decibel Therapeutics Announce Multi-Year Collaboration in Support of Clinical Development for Hearing Loss, Tinnit...
September 26 2018 - 8:30AM
Business Wire
Decibel to Unify Data and Scale with Medidata
Cloud
News summary:
- Boston biotech company selects Medidata
Cloud to unify clinical trial data
- Decibel adopts Medidata ePRO/eCOA and
eTMF to rapidly scale and expand research
- Medidata Cloud to support clinical
development for hearing loss, tinnitus, and balance disorders
Full Story:
Medidata (NASDAQ:MDSO) today announced that Decibel Therapeutics
is adopting Medidata Cloud, the Intelligent Platform for Life
Sciences. The agreement will support the Boston biotech company’s
clinical development for hearing loss, tinnitus, and balance
disorders.
Decibel is advancing a portfolio of research programs addressing
inner ear disorders with its discovery and development product
engine. As it prepares to ramp up both interventional and
non-interventional clinical research activities, Decibel partnered
with Medidata to:
- Support early stage research in the
areas of observational, natural history explorations
- Facilitate timely data capture and
analysis of study outcomes
- Seamlessly scale and unify all data by
adopting one eClinical platform across studies
“As we establish our clinical operations infrastructure, we are
not only focusing on speed and quality, but building a clinical
data ecosystem that is scalable and cost effective. Medidata
supports these initiatives, and facilitates the aggregation and
analysis of clinical data across a variety of platforms and
studies,” said Heather Wolff, senior director of clinical
development operations at Decibel. “After an extensive search,
Medidata surfaced as the ideal technology partner for Decibel.”
Decibel will incorporate key Medidata offerings as it advances
its hearing and balance-related research programs:
- Edge eTMF: unify content, data, and
workflows with comprehensive real-time, end-to-end TMF management
and share with other clinical partners
- Rave ePRO/eCOA: optimize data accuracy
and patient engagement by automating the collection of
patient-reported clinical trial information from mobile devices
into the Medidata Cloud
“We’re excited to support Decibel as they break new ground in
the development of novel therapeutics for inner ear disorders,”
said Glen de Vries, president and co-founder, Medidata. “Our one
platform approach empowers innovative companies around the world,
like Decibel, to scale their research and make new
discoveries.”
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users everyday to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
About Decibel Therapeutics, Inc.
Decibel Therapeutics has established the world’s first
comprehensive drug discovery, development, and translational
research platform to discover and develop therapeutics to protect,
repair, and restore hearing. To serve the over half a billion
people globally living with hearing loss and related disorders,
Decibel is committed to creating a world in which the benefits and
joys of hearing are available to all. Decibel is headquartered in
Boston, Mass.
For more information about Decibel Therapeutics, please visit
www.decibeltx.com or follow @DecibelTx on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180926005244/en/
MedidataInvestors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024